Comparative clinical outcomes of polymyxin-based versus non-polymyxin regimens as definitive therapy in Carbapenem-resistant Klebsiella pneumoniae bacteraemia
Divya Bhat, Asha K Rajan, Vandana Kalwaje Eshwara, Muralidhar Varma, Shashikiran Umakanth, Girish Thunga, Vishal Shanbhag · 2026
Read Comparative clinical outcomes of polymyxin-based versus non-polymyxin regimens as definitive therapy in Carbapenem-resistant Klebsiella pneumoniae bacteraemia by Divya Bhat, Asha K Rajan, Vandana Kalwaje Eshwara, Muralidhar Varma, Shashikiran Umakanth, Girish Thunga, Vishal Shanbhag (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0353799.txt.
Description
Bhat and colleagues compared two drug plans for a hard-to-treat blood infection in a 2026 study. The germ, a pneumonia-causing bacterium, no longer responds to a key family of strong antibiotics, leaving few choices. Records from several hospitals covered adults treated from 2019 through 2023 with either an older drug family or newer alternatives.
Patients on newer alternatives cleared fever more often and left hospital alive more often than those on the older drugs. Kidney harm was also less common in that group, while germ clearing from blood was similar. The older drug family itself predicted higher risk of death. The results favor moving away from the older drugs when a newer option is available.
Catalog record
| CREATOR | Divya Bhat, Asha K Rajan, Vandana Kalwaje Eshwara, Muralidhar Varma, Shashikiran Umakanth, Girish Thunga, Vishal Shanbhag |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47277 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |